Companies › Immunic
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vidofludimus (IMU-838) Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 3 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis (RRMS) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05201638 | Vidofludimus (IMU-838) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | Neurology | Nov 2026 |
| NCT05134441 | Vidofludimus (IMU-838) | Phase 3 | Multiple Sclerosis | Neurology | Nov 2026 |
| NCT03846219 | Vidofludimus (IMU-838) | Phase 2 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Neurology | Dec 2029 |
Cash of $155m on 2026-06-30; operating cash outflow about $98m a year; runway about 19 months at that burn, to Jan 2028; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Alpha Cognition NervGen Pharma Satellos Bioscience Coya Therapeutics PepGen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.